Table 1 Clinical characteristics of breast cancer patients with poor (cases) and favorable (controls) invasive disease-free survival

Number of patients

208

208

Age at diagnosis

 < 0.01^a

Mean (SD)

56 (15)

52 (11)

Range

23—90

27—83

N (%)

N (%)

Age at diagnosis

 < 0.01^b

 23–39

28 (13.5%)

25 (12.0%)

 40–49

50 (24.0%)

77 (37.0%)

 50–59

51 (24.5%)

57 (27.4%)

 60–69

38 (18.3%)

31 (14.9%)

 70–90

41 (19.7%)

18 (8.7%)

Menopausal status at diagnosis

 < 0.01^b

 Premenopausal

69 (33.2)

101 (48.6)

 Postmenopausal

121 (58.2)

98 (47.1)

 Unknown

18 (8.7)

9 (4.3)

Stage

 < 0.01^b

 Stage I

19 (9.1)

45 (21.6)

 Stage II

100 (48.1)

127 (61.1)

 Stage III

89 (42.8)

36 (17.3)

Molecular subtype ^*

 < 0.01^c

 Luminal A

38 (18.3)

47 (22.6)

 Luminal B

83 (39.9)

86 (41.3)

 TNBC

37 (17.8)

42 (20.2)

 HER2-enriched

23 (11.1)

26 (12.5)

 Unclassified

27 (13.0)

7 (3.4)

Estrogen receptor, ER

1.00²

 Negative

75 (36.1)

75 (36.1)

 Positive

133 (63.9)

133 (63.9)

Progesterone receptor, PR

0.62^b

 Negative

96 (46.2)

91 (43.8)

 Positive

112 (53.8)

117 (56.2)

Human epidermal growth factor receptor-2, HER2

 Negative

123 (59.1)

143 (68.8)

 Positive

61 (29.3)

65 (31.2)

 Unknown

24 (11.5)

0 (0.0)

Primary surgery

0.24^b

 Breast conserving

23 (11.1)

35 (16.8)

 Mastectomy

148 (71.2)

138 (66.3)

 Unknown

37 (17.8)

35 (16.8)

Chemotherapy ^d

 < 0.01^c

 No

23 (11.1)

9 (4.3)

 Yes

139 (66.8)

186 (89.4)

 Unknown

46 (22.1)

13 (6.2)

Radiotherapy ^d

 No

103 (49.5)

97 (46.6)

 Yes

86 (41.3)

111 (53.4)

 Unknown

19 (9.1)

0 (0.0)

Hormonal therapy ^d

 < 0.01^b

 No

64 (30.8)

80 (38.5)

 Yes

98 (47.1)

115 (55.3)

 Unknown

46 (22.1)

13 (6.2)